ConductScience.org, home

Trial · NCT00943111

Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPercentage of Participants Who Remained Stable for 52 Weeks During the Primary Analysis PeriodBaseline up to Week 52
For a participant to be classified as stable, the participant must have remained stable in hematological parameters (hemoglobin levels and platelet counts) and organ volumes (spleen, when applicable, and liver volumes in multiples of normal \[MN\]). Stable hematological parameters were defined as hemoglobin level did not decrease more than (\>) 1.5 gram per deciliter (g/dL) from baseline and platelet count did not decrease \>25% from baseline. Stable organ volumes were defined as spleen volume (in MN) did not increase \>25% from baseline, if applicable, and liver volume (in MN) did not increase \>20% from baseline.
PrimaryPercentage of Participants Who Remained Stable Annually for 4 Years During the LTTPWeek 52 up to week 208
For a participant to be classified as stable, the participant must have remained stable in hematological parameters (hemoglobin levels and platelet counts) and organ volumes (spleen, when applicable, and liver volumes in MN). Stable hematological parameters were defined as hemoglobin level did not decrease \>1.5 g/dL from baseline and platelet count did not decrease \>25% from baseline. Stable organ volumes were defined as spleen volume (in MN) did not increase \>25% from baseline, if applicable, and liver volume did not increase \>20% from baseline.
SecondaryTotal T-Scores for Bone Mineral DensityBaseline
Images of the spine and bilateral femur were obtained by dual energy X-Ray absorptiometry (DXA) to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score greater than \[\>\]-1), osteopenia (score -2.5 to less than or equal to \[\<=\] -1), and osteoporosis (score \<= -2.5).
SecondaryAbsolute Change From Baseline in Total T-Scores for Bone Mineral Density at Week 52Baseline, Week 52
Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score \>-1), osteopenia (score -2.5 to \<=-1), and osteoporosis (score \<= -2.5). Absolute change = T-score at Week 52 minus T-score at baseline.
SecondaryTotal Z-Scores for Bone Mineral DensityBaseline
Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \>-2) and below normal (score \<=-2).
SecondaryAbsolute Change From Baseline in Total Z-Scores for Bone Mineral Density at Week 52Baseline, Week 52
Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \>-2) and below normal (score \<=-2). Absolute change = Z-score at Week 52 minus Z-score at baseline.
SecondaryHemoglobin LevelBaseline
SecondaryAbsolute Change From Baseline in Hemoglobin Levels at Week 52Baseline, Week 52Absolute change = hemoglobin level at Week 52 minus hemoglobin level at baseline.
SecondaryPercent Change From Baseline in Platelet Counts at Week 52Baseline, Week 52Percent change in platelet counts = (\[platelet count at Week 52 minus platelet count at baseline\] divided by \[platelet count at baseline\]) multiplied by 100.
SecondaryPercent Change From Baseline in Spleen Volume (MN) at Week 52Baseline, Week 52Percent change in spleen volume = (\[spleen volume at Week 52 minus spleen volume at baseline\] divided by \[spleen volume at baseline\]) multiplied by 100, where all volumes are in MN.
SecondaryPercent Change From Baseline in Liver Volume (in MN) at Week 52Baseline, Week 52Percent change in liver volume = (\[liver volume at Week 52 minus liver volume at baseline\] divided by \[liver volume at baseline\]) multiplied by 100, where all volumes are in multiples of normal.
SecondaryAbsolute Change From Baseline in Total T-Scores for Bone Mineral Density at Week 208Baseline, Week 208
Images of the spine and bilateral femur were obtained by DXA to determine T-score for each bone area and total bone mineral density. T-score compares participant's bone density with that of healthy young participant. The T-score bone density categories are: normal (score \>-1), osteopenia (score -2.5 to \<=-1), and osteoporosis (score \<= -2.5). Absolute change = T-score at Week 208 minus T-score at baseline.
SecondaryAbsolute Change From Baseline in Total Z-Scores for Bone Mineral Density at Week 208Baseline, Week 208
Images of the spine and bilateral femur were obtained by DXA to determine Z-score for each bone area and total bone mineral density. The Z-score bone density categories are: normal (score \>-2) and below normal (score \<=-2). Absolute change = Z-score at Week 208 minus Z-score at baseline.
SecondaryAbsolute Change From Baseline in Hemoglobin Levels at Week 208Baseline, Week 208Absolute change = hemoglobin level at Week 208 minus hemoglobin level at baseline.
SecondaryPercent Change From Baseline in Platelet Counts at Week 208Baseline, Week 208Percent change in platelet counts = (\[platelet count at Week 208 minus platelet count at baseline\] divided by \[platelet count at baseline\]) multiplied by 100.
SecondaryPercent Change From Baseline in Spleen Volume (in MN) at Week 208Baseline, Week 208Percent change in spleen volume = (\[spleen volume at Week 208 minus spleen volume at baseline\] divided by \[spleen volume at baseline\]) multiplied by 100, where all volumes are in MN.
SecondaryPercent Change From Baseline in Liver Volume (in MN) at Week 208Baseline, Week 208Percent change in liver volume = (\[liver volume at Week 208 minus liver volume at baseline\] divided by \[liver volume at baseline\]) multiplied by 100, where all volumes are in multiples of normal.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00943111/registered